Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
|EU record number
|Company / Sponsor
|Phase III trial investigating a AAV vector containing a variant of human factor IX gene administered to adult subjects with severe or moderately-severe hemophilia B
|uniQure biopharma B.V.
|Recombinant adeno associated viral vector containing the wild type modified to express the Padua derivative of human coagulation factor IX cDNA
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2015.
|A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
|Catapult Cell Therapy
|Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)
|Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis
|Gene coding for the human interleukin-10 (hIL-10)